Alterity Therapeutics Limited Stock
Stocks
ATH
AU0000043945
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Australian S.E.
04:10:28 06/11/26 pm AEDT
|
5-day change | 1st Jan Change | ||
| 0.2650 AUD | -7.02% |
|
0.00% | -33.75% |
| 05/10 | Alterity Therapeutics Limited Presents New Analyses of Ath434 Phase 2 Data in Multiple System Atrophy | CI |
| 16/09 | Lake Street Initiates Alterity Therapeutics at Buy With $10 Price Target | MT |
| Market Cap | 41.75M 37.44M 34.22M 31.24M 58.86M 3.92B 60.71M 412M 164M 2.09B 157M 153M 6.61B | P/E 2027 * |
-2.59x | P/E 2028 * | -0.24x |
|---|---|---|---|---|---|
| Enterprise Value | 31.8M 28.52M 26.06M 23.79M 44.83M 2.99B 46.24M 314M 125M 1.59B 119M 117M 5.03B | EV / Sales 2027 * |
25.2x | EV / Sales 2028 * | 2.11x |
| Free-Float |
96.2% | Yield 2027 * |
-
| Yield 2028 * | - |
| Markets | Quality | ||
|---|---|---|---|
Australian S.E.
| ATH | Delayed | |
OTC Markets
| PRNAF | Delayed | |
|
Deutsche Boerse AG
| PBN | Delayed | |
|
Börse Stuttgart
| PBN | Delayed |
Last Transcript: Alterity Therapeutics Limited
| 1 day | -7.02% | ||
| 1 month | -33.75% | ||
| 3 months | -49.52% | ||
| 6 months | -47.00% | ||
| Current year | -33.75% |
| 1 week | 0.24 |  | 0.31 |
| 1 month | 0.23 | | 0.4 |
| Current year | 0.23 | | 0.78 |
| 1 year | 0.23 | | 0.78 |
| 3 years | 0.1 | | 0.95 |
| 5 years | 0.1 | | 1.5 |
| 10 years | 0.1 | | 20.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 65 | 07/01/2021 |
| Director of Finance/CFO | - | 30/09/2024 | |
| Chief Tech/Sci/R&D Officer | - | 01/04/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Marks
BRD | Director/Board Member | 70 | 29/07/2005 |
Lawrence Gozlan
BRD | Director/Board Member | 47 | 08/08/2011 |
David Stamler
BRD | Director/Board Member | 65 | 21/11/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 31/8/26 | Exercice | Director | 47,620 | 0.0216% | ||
| 31/8/26 | Buy | Chief Executive Officer | -47,620 | 0.0216% | ||
| 31/8/26 | Buy | Director | 95,240 | 0.0432% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -7.02% | 0.00% | -47.00% | -24.29% | 41.75M | |
| -4.83% | +3.51% | +53.62% | +61.75% | 65.94B | |
| -1.34% | +2.98% | +24.79% | +100.18% | 56.53B | |
| +0.02% | +1.07% | +10.63% | +76.66% | 56.88B | |
| +5.09% | +9.89% | +22.45% | +107.48% | 46.49B | |
| +2.62% | +1.68% | +28.91% | +37.01% | 44.8B | |
| +8.24% | +0.51% | +213.26% | +792.66% | 41.59B | |
| -1.86% | +10.13% | +26.82% | +53.22% | 35.35B | |
| -2.97% | -9.84% | +88.86% | +76.17% | 33.29B | |
| -2.18% | +7.06% | +36.06% | -4.95% | 24.92B | |
| Average | -0.42% | +2.93% | +45.84% | +127.59% | 40.58B | |
| Weighted average by Cap. | +0.21% | +3.40% | +53.11% | +142.94% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 1.26M 1.13M 1.04M 946K 1.78M 119M 1.84M 12.49M 4.98M 63.41M 4.75M 4.64M 200M | 2.28M 2.04M 1.87M 1.71M 3.21M 214M 3.31M 22.52M 8.98M 114M 8.56M 8.37M 361M |
| Net income | -27.2M -24.4M -22.3M -20.35M -38.35M -2.56B -39.56M -269M -107M -1.36B -102M -99.91M -4.31B | -29.15M -26.15M -23.9M -21.81M -41.1M -2.74B -42.39M -288M -115M -1.46B -109M -107M -4.62B |
| Net Debt | -9.95M -8.93M -8.16M -7.45M -14.03M -936M -14.47M -98.34M -39.21M -499M -37.36M -36.56M -1.58B | -36.93M -33.13M -30.27M -27.64M -52.07M -3.47B -53.71M -365M -146M -1.85B -139M -136M -5.85B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/11/26 | $0.2650 | -7.02% | 67,367 |
| 05/11/26 | $0.2850 | -1.72% | 134,349 |
| 04/11/26 | $0.2900 | +20.83% | 1,064,323 |
| 03/11/26 | $0.2400 | -5.88% | 354,162 |
| 02/11/26 | $0.2550 | -3.77% | 37,809 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ATH Stock
Select your edition
All financial news and data tailored to specific country editions
